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(See the major article by Polley et al on pages 637–44.)
Background. Current malaria diagnostic tests, including microscopy and antigen-detecting rapid tests, cannot
reliably detect low-density infections. Molecular methods such as polymerase chain reaction (PCR) are highly sensi-
tive but remain too complex for ﬁeld deployment. A new commercial molecular assay based on loop-mediated iso-
thermal ampliﬁcation (LAMP) was assessed for ﬁeld use.
Methods. Malaria LAMP (Eiken Chemical, Japan) was evaluated for samples from 272 outpatients at a rural
Ugandan clinic and compared with expert microscopy, nested PCR, and quantitative PCR (qPCR). Two technicians
performed the assay after 3 days of training, using 2 alternative blood sample–preparation methods and visual inter-
pretation of results by ﬂuorescence assay.
Results. Compared with 3-well nested PCR, the sensitivity of both LAMP and single-well nested PCR was 90%;
the microscopy sensitivity was 51%. For samples with a Plasmodium falciparum qPCR titer of ≥2 parasites/µL,
LAMP sensitivity was 97.8% (95% conﬁdence interval, 93.7%–99.5%). Most false-negative LAMP results involved
samples with parasitemia levels detectable by 3-well nested PCR but very low or undetectable by qPCR.
Conclusions. Malaria LAMP in a remote Ugandan clinic achieved sensitivity similar to that of single-well nested
PCR in a United Kingdom reference laboratory. LAMP dramatically lowers the detection threshold achievable in
malaria-endemic settings, providing a new tool for diagnosis, surveillance, and screening in elimination strategies.
Keywords. malaria; diagnosis; LAMP; loop-mediated isothermal ampliﬁcation; sensitivity and speciﬁcity; PCR;
polymerase chain reaction; molecular diagnosis; DNA; Plasmodium falciparum; Uganda; Africa.
Accurate detection of malaria is of increasing impor-
tance as the malaria prevalence declines across much of
its range [1, 2],with surveillance and screening becoming
increasingly important in program management [3–5].
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Microscopy and antigen-detecting rapid diagnostic tests (RDTs),
when performed correctly, provide accurate diagnosis for case
management [6] but cannot reliably detect lower-density para-
sitemia that may occur in asymptomatic individuals, who then
represent reservoirs of infection. Such low-density infections
with Plasmodium species are widely documented [7–12] and
may contribute to transmission [13–15]. To eliminate malaria
and prevent reintroduction, sustaining the capacity to detect
such infections will be critical. The development of ﬁeld-ready
assays that can detect foci of infection in a way timely enough
to enable treatment is therefore recognized as a major priority
for malaria elimination [3, 16, 17]. Such highly sensitive assays
could also beneﬁt antimalarial drug efﬁcacy monitoring, vaccine
studies, and screening of vulnerable populations, such as preg-
nant women, in which low-density infections may have signiﬁ-
cant clinical consequences [18–20].
Polymerase chain reaction (PCR) detects parasite DNA, can
identify infections below the threshold of detection for micros-
copy and RDTs, and is commonly considered the gold standard
to detect malaria infection. However, PCR requires sophisticat-
ed laboratory infrastructure and advanced training, making it
challenging and costly to implement in most malaria-endemic
areas. Although PCR is used in some cases for focal screening
and treatment strategies [11, 21], its restriction to central refer-
ence laboratories, often far from the sampled population,
greatly limits its usefulness.
Loop-mediated isothermal ampliﬁcation (LAMP) may offer
a practical alternative. Like PCR, LAMP is a molecular tech-
nique that ampliﬁes nucleic acids but uses simpler equipment
and is less time intensive. A prototype LAMP assay designed
for use in resource-constrained settings was developed through
a public/private collaboration between the Foundation for In-
novative New Diagnostics, Switzerland, and Eiken Chemical
Co., Ltd., Japan. The assay forms the basis for a CE-marked
product commercially released in July 2012 as the Loopamp
Malaria Pan/Pf Detection Kit, list number LMC562 (Eiken
Chemical). It is consistent with a recent description of “an ideal
LAMP detection format” [22], and the kit consists of vacuum-
dried reagents stable at ambient temperature. The assay’s
primers target Plasmodium genus or P. falciparum–speciﬁc se-
quences. Assay performance includes either of 2 simple blood-
processing methods, a 40-minute reaction time in a closed am-
pliﬁcation unit, and a visual readout. The result is essentially
qualitative. The relative simplicity and robustness of LAMP
opens the potential for sustainable nucleic acid ampliﬁcation in
laboratories and near-patient locations in malaria-endemic
countries. An evaluation of the LAMP test kit in a United
Kingdom reference laboratory, reported in the article by Polley
et al in this issue of the Journal, showed that LAMP sensitivity
approximated that of nested PCR [23]. This article presents
results of the same kit evaluated in a rural clinic in Uganda.
METHODS
Ethics and Protocol
All participants, or their parents or guardians, provided written
informed consent. LAMP results did not inﬂuence care of pa-
tients. The study protocol was approved by the Uganda Nation-
al Council of Science and Technology (UNCST; reference
HS160) before participant recruitment and sample collection
began (Supplementary Materials). The study and report follow
STARD (Standards for the Reporting of Diagnostic Accuracy
Studies) guidelines (Supplementary Materials).
Study Site and Population
The study was conducted from November 2010 to February
2011 in Tororo District, eastern Uganda, at Nagongera Health
Center, a government-sponsored health facility where malaria
diagnosis is based on microscopy. A portable generator was
used to ensure a stable electrical current for the LAMP incuba-
tor and other study equipment. The entomological inoculation
rate in this area in 2001–2002 was estimated to be 562 infective
bites per person per year [24]. A 2008 study in this area found
that 31% of symptomatic patients aged ≥5 years tested positive
by expert microscopy (H. Hopkins et al, unpublished data),
whereas a year earlier 39% were found positive by a combination
of microscopy and PCR [25].P. falciparum accounts for the great
majority of malaria cases (≥94%) in this region [26–28].
Study selection criteria included patient age of ≥5 years, docu-
mented presence of fever or self-reported history of fever within
the previous 24 hours, and absence of evidence of severe illness.
Sample Size and Sample Collection
Sample size calculations were based on the assumption of a
microscopy-conﬁrmed prevalence of malaria of 30% among
symptomatic patients and a LAMP sensitivity of 95% (95%
conﬁdence interval [CI], 90%–98%) and speciﬁcity of 80%
(95% CI, 75%–85%) for P. falciparum, compared with expert
microscopy; calculations revealed that 351 participants were re-
quired. A target of 380 participants was set. Over 18 days, con-
secutive outpatients referred to the laboratory for malaria
testing by clinic staff according to the usual standard of care
were asked to participate in the study. Study personnel were not
involved in the decision to refer patients to the laboratory or in
any decision regarding clinical management. At enrollment,
the patient’s age, sex, and axillary temperature were recorded; a
2–3-mL venous blood sample was collected in a tube contain-
ing ethylenediaminetetraacetic acid (EDTA) for preparation of
blood smears and determination of white blood cell count; and
a 2-mL heparinized sample was collected and stored at ambient
temperature until LAMP was performed the same day. Four
hundred microliters of the EDTA sample was stored for up to 4
days at 4°C before freezing at −80°C.
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LAMP
The LAMP assay used in this study is based on a published mi-
tochondrial P. falciparum–speciﬁc primer set [29]; the LAMP
kits consisted of plastic reaction tubes containing thermosta-
ble vacuum-dried reagents that were speciﬁc for ampliﬁcation
of P. falciparum DNA. A successful reaction results in large
quantities of DNA and insoluble magnesium orthophosphate,
a byproduct of ampliﬁcation that can be detected by ﬂuorescence
assay (using calcein as an indicator) or by turbidimetry [29]; this
study used only ﬂuorescence reading.
After blood sample processing by one of 2 methods de-
scribed below, the assay was performed according to the manu-
facturer’s instructions by 2 laboratory technologists with 3 days
of training in the test procedure. In short, 25 µL of processed
blood was added to reaction tubes, and reagents were reconsti-
tuted by shaking the tubes. The tubes were placed into the LF-
160 LAMP incubator (Eiken), which accommodates 16 tubes
per run; each run consisted of incubation for 40 minutes at 65°
C, followed by incubation for 5 minutes at 80°C to inactivate
the enzyme and halt ampliﬁcation. Reaction tubes were then
read in the ﬂuorescence visualization unit under blue light-
emitting diode light (integral to the LF-160 incubator). Positive
and negative controls were included in each run. The test kits
and controls, sealed at the time of manufacture in moisture-
proof packaging, had been stored at room temperature in
Uganda for 4 weeks before use. Storage temperature was moni-
tored but not controlled and remained at ≤30°C.
A LAMP reaction was considered positive for P. falciparum
DNA if an obvious increase in ﬂuorescence was observed, com-
pared with the negative control. Results were read by a single
laboratory technologist and were considered valid if ﬂuores-
cence was present in the positive control and absent in the neg-
ative control. LAMP results were interpreted by study staff; the
interpreter of each result was blinded to LAMP results for the
same sample using the alternative sample-preparation method
and to health facility microscopy results. In the case of vague or
indeterminate LAMP results, the second technologist con-
ﬁrmed the reading in real time.
Two sample-preparation methods to extract DNA from
patient blood were used for this study: a commercially available
kit designed speciﬁcally for LAMP (Loopamp PURE DNA Ex-
traction Kit) and a boil and spin method. As described in the
accompanying article by Polley et al [23], the PURE device is a
series of interlocking plastic components providing a closed
system for preparation of a 35-μL blood aliquot without centri-
fugation or micropipetting. For the boil and spin method,
60 μL of blood was added to 60 μL of extraction solution (400
mM NaCl, 40 mM Tris pH 6.5, and 0.4% sodium dodecyl
sulfate) in an Eppendorf tube, heated for 5 minutes at 95°C
with a water bath, and centrifuged at 10 000 × g for 1 minute;
25 µL of the supernatant was pipetted into a dilution tube con-
taining 287.5 μL of molecular-grade water (Qiagen, Germany);
and 25 µL of the resulting solution was transferred into a reac-
tion tube for use in the LAMP assay. Complete standard operat-
ing procedures for the LAMP assay, PURE, and boil and spin
method are online (available at: http://www.ﬁnddiagnostics.
org/programs/malaria-afs/lamp/standard_procedures/index.html).
Estimates of sample inputs for LAMP and PCR are as follows:
25 µL of PURE extract contains P. falciparum DNA equivalent
to the number of parasite genomes in 2.8 µL of the original
blood sample (conﬁrmed experimentally by S. Polley [unpub-
lished data]), and 2 µL of boil and spin extract (prior to 12.5 ×
dilution) contains P. falciparum DNA equivalent to 1.6 µL of
the original blood sample (assuming 80% recovery of DNA).
The volume of Qiagen DNA extract used for PCR is equivalent
to 10 µL of the original blood sample (assuming 100% recovery).
Microscopy
Blood smears were stained with 3% Giemsa for 35 minutes and
mounted with a coverslip and DPX. Leukocyte count was mea-
sured on site, using a KX-21 hematology analyzer (Sysmex,
Tokyo, Japan) or a HemoCue point-of-care instrument (Quest
Diagnostics, Ängelholm, Sweden), to allow accurate calculation
of parasite density. One thick smear was prepared and read im-
mediately by health facility staff for use in case management. A
second thick smear and a thin smear were prepared by study
staff and read by 2 expert microscopists (expertise level 1 or 2,
following the World Health Organization [WHO] competency
assessment protocol [30]) after completion of study enrollment.
Thick smears were read for parasite density, and thin smears
were read for parasite species. Smears with discrepant results
were reread by a third expert reader. All microscopists were
blinded to results of LAMP and previous microscopy.
PCR
Nested PCR provided the reference standard for assessment of
LAMP performance. Whole blood samples stored at −80°C
were shipped from Uganda on dry ice to the Hospital for Tropi-
cal Diseases in London, United Kingdom, and analyzed by
PCR to conﬁrm the presence or absence of parasite DNA. PCR
was performed according to standardized protocols and pub-
lished methods [31, 32], as detailed in the accompanying article
by Polley et al [23]. Results were independently scored by 2 in-
vestigators blinded to microscopy and LAMP results.
After nested PCR was performed for P. falciparum with a
single well for each sample, nested PCR was repeated in 3 wells
for samples that tested negative in the ﬁrst run, 3 random posi-
tive samples, and the within-run negative controls, increasing
the overall sensitivity of the reference standard. A sample was
rescored as testing positive if any of the replicate PCR reactions
yielded an amplicon of the correct size.
All samples positive for P. falciparum DNA by nested PCR
underwent real-time quantitative PCR (qPCR) analysis. Two
microliters of Qiagen-extracted DNA was used in a multiplex
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real-time PCR to detect P. falciparum, Plasmodium malariae,
Plasmodium vivax, and both subspecies of Plasmodium ovale [33]
as described in the accompanying article [23]. To determine
the P. falciparum density, a dilution series of the WHO interna-
tional standard for P. falciparum DNA was included in each
run [33], together with DNA from a clinical P. falciparum
sample conﬁrmed by microscopy to contain 5000 parasites/μL.
This qPCR assay provided a limit of detection of 1 parasite/μL.
All P. falciparum samples that were positive by nested PCR but
negative by qPCR were therefore assumed to have parasite den-
sities of <1 parasite/μL.
Data Management and Statistical Analysis
LAMP and microscopy data were double entered into an EpiInfo,
version 6.04, database (Centers for Disease Control and Preven-
tion, Atlanta, GA). PCR data were entered in Microsoft Ofﬁce
Excel 2007. Data were analyzed with Stata, version 9, (Stata,
College Station, TX), and exact binomial CIs were calculated.
Figure 1. Flow diagram of the study. The diagram summarizes results of the loop-mediated isothermal ampliﬁcation (LAMP) malaria assay for Plasmodi-
um falciparum at a remote clinical site in Uganda, using 2 alternative simple sample-preparation methods (PURE device and boil and spin), and results of 2
reference standards: single-well nested polymerase chain reaction (nPCR) and 3-well nPCR. The number of samples positive by nPCR increased by 20 after
inclusion of 3-well nPCR results. Results of expert microscopy and of quantitative PCR (qPCR) to determine P. falciparum titer and presence of various Plas-
modium species are presented in the text. Most false-negative LAMP results occurred in samples with parasite titers that were very low or undetectable
by qPCR (Table 3); no sample with a titer of ≥1 parasite/μL was missed by both LAMP methods. False-positive LAMP results may represent errors in
sample-preparation technique or detection of low-density parasitemias that were undetected by nPCR because of stochastic effects in sampling.
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RESULTS
During the study, errors were noted in the informed consent
process, and on consultation with UNCST, samples and data
from 197 participants with possible consent errors were exclud-
ed from analysis. Data were therefore evaluated from 272 pa-
tients referred for malaria testing at Nagongera Health Center
in eastern Uganda (Figure 1). Table 1 shows characteristics of
the study population. Fifty-two participants (19.1%) were aged
5–10 years, 69 (25.4%) were aged 11–20 years, and 151 (55.1%)
were aged ≥21 years. All self-reported a history of fever, while
8.2% had an elevated axillary temperature (deﬁned as an axil-
lary temperature of ≥37.2°).
PCR Results
Single-well nested PCR found 179 samples (65.8%) to be posi-
tive for P. falciparum DNA. The number of positive samples in-
creased to 199 (73.2%) after 3-well nested PCR was performed
(Figure 1). Of the additional 20 samples that tested positive by
3-well PCR, the qPCR-determined P. falciparum density was
<1 parasite/µL in 9 and undetectable in 11. Of all 199 samples
that tested positive by nested PCR, parasite DNAwas detectable
by qPCR in 178. Of these 178 samples, the qPCR assay identi-
ﬁed 121 (68.0%) as P. falciparum monoinfections; 38 (21.4%)
as P. falciparum and P. malariae mixed infections; 10 (5.6%) as
P. falciparum, P. malariae, and P. ovale mixed infections; 8
(4.5%) as P. falciparum and P. ovale mixed infections; and 1
(0.6%) as P. ovale monoinfection. Since the sample identiﬁed
by qPCR as a P. ovale monoinfection was found to contain
P. falciparum DNA by nested PCR, it was most likely a mixed
infection containing a level of P. falciparum that was below
the detection threshold of qPCR. For the 176 infections with
qPCR-detectable P. falciparum DNA, the median titer by qPCR
was 34 parasites/µL (range, <1–259 442 parasites/µL).
LAMP Performance, Compared With Reference Standards
Of the 272 total samples, 181 (66.5%) prepared with the PURE
device and 190 (69.9%) prepared by the boil and spin method
were positive by LAMP. Agreement between PURE and boil
and spin results was 91% (κ=0.79).
Compared with single-well nested PCR, LAMP performed
on samples prepared with PURE had a sensitivity, speciﬁcity,
positive predictive value (PPV), and negative predictive value
(NPV) of 93.3%, 85.0%, 92.3%, and 86.8%, respectively. For
samples prepared by boil and spin, results were 93.9%, 76.3%,
88.4%, and 86.6%, respectively. When 3-well nested PCR was
used as the gold standard, sensitivity, speciﬁcity, PPV, and
NPV were 89.5%, 95.9%, 98.3%, and 76.9%, respectively, for
PURE and 90.0%, 84.9%, 94.2%, and 75.6%, respectively, for
boil and spin. For all samples, when compared with 3-well
nested PCR, the LAMP assay’s sensitivity (with PURE, 89.5%
[178/199]; with boil and spin, 90.0% [179/199]) approximated
that of single-well nested PCR (90.0% [179/199]). When analy-
sis was restricted to samples with a P. falciparum titer of ≥1
parasite/μL by qPCR, the sensitivity of LAMP with PURE,
compared with 3-well nested PCR, increased to 97.3% (95% CI,
93.3%–99.3%), and the sensitivity of LAMP with boil and spin
increased to 98.0% (95% CI, 94.2%–99.6%; Table 2). When the
Table 1. Characteristics of 272 Study Subjects
Characteristic Value
Age, y
Median 23
Range 5–81
Interquartile range 14–32
Female sex 173 (63.6)
Self-reported history of fever 272 (100)
Measured elevated temperaturea 22/268a (8.2)b
Data are for 272 subjects, unless otherwise indicated.
a Defined as an axillary temperature of ≥37.2°C; data were missing for 4
participants. Three participants (1.1%) had an axillary temperature of ≥38.0°C.
Table 2. Loop-Mediated Isothermal Ampliﬁcation (LAMP)
Sensitivity, Compared With 3-Well Nested Polymerase Chain
Reaction (nPCR), Stratiﬁed by Quantitative PCR (qPCR)–Determined
Parasite Density
P. falciparum Density,a
Preparation Method
Subjects,
Proportionb
Sensitivity,
% (95% CI)
<1 parasite/µL
PURE 33/50c,d 66.0 (51.2–78.8)
Boil and spin 33/50c,d 66.0 (51.2–78.8)
≥1 parasite/µL
PURE 145/149 97.3 (93.3–99.3)
Boil and spin 146/149 98.0 (94.2–99.6)
≥2 parasites/µL
PURE 134/137 97.8 (93.7–99.5)
Boil and spin 134/137 97.8 (93.7–99.5)
≥5 parasites/µLe
PURE 119/122 97.5 (93.0–99.5)
Boil and spin 119/122 97.5 (93.0–99.5)
Abbreviations: CI, confidence interval; P. falciparum, Plasmodium falciparum.
a Determined by qPCR.
b Data are no. of samples positive by LAMP/no. of samples positive by the
gold standard of nPCR.
c Includes 23 samples with parasites detected by nPCR with 3-well assay but
not detectable by multiplex real-time qPCR. These results are therefore
assumed to represent very-low-density infections below the limit of detection
of the qPCR assay (ie, 1 parasite/μL for P. falciparum).
d Of the 50 samples positive by 3-well nPCR and with a P. falciparum titer of
<1 parasite/µL by qPCR, 29 (58%) had parasites detected by LAMP with both
PURE and boil and spin sample-preparation methods, 4 each (8%) had
parasites detected only with either PURE or boil and spin, and 13 (26%) did
not have parasites detected by LAMP with either sample-preparation method.
e Five parasites per microliter is the lower limit of detection targeted in LAMP
product specifications.
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threshold was raised to a P. falciparum titer of ≥2 parasites/µL, the
sensitivity of LAMP with both preparation methods was 97.8%
(95% CI, 93.7%–99.5%), compared with 3-well nested PCR.
As shown in Table 3, most false-negative LAMP results oc-
curred in samples with parasite titers that were very low or un-
detectable by qPCR. Parasites in 4 samples with a higher
parasite density were missed by LAMP with PURE, and para-
sites in 3 were missed by LAMP with boil and spin; these were
different samples, and no sample with a titer of ≥1 parasite/μL
tested negative by both methods (Table 3). The sample men-
tioned earlier, with P. ovale monoinfection detected by qPCR
(and P. falciparum detected by nested PCR), was negative by
P. falciparum LAMP, using both preparation methods. Twelve
samples were negative by 3-well nested PCR (and by microsco-
py) but positive by LAMP with PURE alone (n = 1), boil and
spin alone (n = 9), or both methods (n = 2; Figure 1).
Expert microscopy detected parasites in 102 samples (37.5%),
with a median density of 196 parasites/μL (range, 11–147 032
parasites/μL). For the 102 microscopy-positive samples, the
median qPCR titer was 176 parasites/µL (range, 0–259 442 para-
sites/µL). Most (97 of 102) were identiﬁed by microscopy as
P. falciparum monoinfections, while 2 were reported as mixed
P. falciparum and P. malariae infections, 2 as P. malariae mono-
infections, and 1 as P. ovalemonoinfection.
LAMP achieved far higher sensitivity than microscopy but
had a lower speciﬁcity, using PCR as a reference standard. This
is consistent with the threshold of detection being close to that
of the reference standard. Compared with single-well nested
PCR, the sensitivity, speciﬁcity, PPV, and NPV of microscopy
were 56.4%, 98.9%, 99.0%, and 54.2%, respectively. With 3-well
PCR as the gold standard, these measures were 51.3%, 100%,
100%, and 42.9%, respectively. One sample negative by LAMP
with both preparation methods was positive by microscopy;
this sample was also negative by single-well nested PCR and
qPCR but positive by 3-well nested PCR, suggesting a very-low-
density infection. Three samples that were positive by micros-
copy (and PCR) were negative by LAMP with PURE, while 3
different samples were negative by boil and spin (Table 3).
DISCUSSION
The malaria LAMP kit used in this study achieved accuracy
comparable to that of nested PCR in a United Kingdom re-
ference laboratory setting [23]. The study reported here demon-
strates similar sensitivity when performed in a remote clinic in
a malaria-endemic area. LAMP results for blood samples pre-
pared with 2 simple methods and read visually by ﬂuorescence
under a blue light-emitting diode light far exceeded the sensi-
tivity of expert microscopy and compared well with a reference
standard of 3-well nested PCR, with very high sensitivity for in-
fections of ≥2 parasites/μL. LAMP results were available within
60–90 minutes of starting sample processing. The results were
achieved by technicians who had no previous training in mo-
lecular diagnostic techniques and just 3 days of training in
LAMP procedures. Sample collection, preparation, and testing
were performed on 1 countertop in a small room at the health
center. The closed ampliﬁcation and reading system reduces
the likelihood of workspace amplicon contamination.
Several evaluations of malaria LAMP assays have reported
detection of cultured parasites or ﬁeld samples transported to
research laboratories [35–38]; one study evaluated another
LAMP assay in a ﬁeld clinic in Thailand, comparing results
with microscopy [39]. To our knowledge, the current study is
the ﬁrst to demonstrate the reliable detection of parasites to a
very low threshold in a remote clinical setting and the ﬁrst to
use ﬁeld-stable reagents. The assay demonstrated a detection
Table 3. Characteristics of Samples With a Plasmodium falciparum Titer of >1 Parasite/μL for Which Loop-Mediated Isothermal
Ampliﬁcation Results Were False-Negative When Compared With the Nested Polymerase Chain Reaction (nPCR) Reference Standard
Expert Microscopy qPCR
Preparation Method,
Sample Identification no. Species
Parasite Density,
Parasites/µL Species
P. falciparum Titer,
Parasites/µL
PURE
33 P. falciparum 39.5 P. falciparum, P. malariae 9.5
501 Negative . . . P. falciparum, P. malariae, P. ovale 1.2
571 P. falciparum 563 P. falciparum 678
581 P. falciparum 743 P. falciparum, P. malariae, P. ovale 1458
Boil and spin
7 P. falciparum 24 P. falciparum 7.4
251 P. falciparum 1327 P. falciparum, P. malariae 529
562 P. falciparum 126 P. falciparum, P. malariae 250
Abbreviations: qPCR, quantitative PCR; P. malariae, Plasmodiummalariae; P. ovale, Plasmodium ovale.
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threshold equivalent to that of single-well nested PCR, when
compared to 3-well nested PCR. Performance of both LAMP
and single-well nested PCR declined in samples containing <1
parasite/μL.
A small number of false-negative results occurred with
samples containing parasite densities well above the limit of de-
tection of expert microscopy. This occurred with both sample-
preparation methods but on different samples, suggesting a
failure in the sample-preparation steps rather than failure of
recognition by the LAMP primer sets. Further investigation
could identify and minimize preparation errors. Some apparent
false-positive LAMP results also occurred; this would pose a
problem for surveillance in settings of very low transmission or
for drug-efﬁcacy monitoring. However, it is unclear from this
study and from the parallel United Kingdom reference labora-
tory study [23] whether these are really false-positive results. At
these low parasite densities, chance discrepancies are expected
because of stochastic processes, and false-positive results may
represent detection of very-low-density parasitemias that were
undetected by the nested PCR reference standard. False-posi-
tive results were not seen during assay development when
testing against parasite-negative samples from areas where
malaria is not endemic, using the sample-preparation methods
described here [23].
The ability to detect very-low-density malaria parasitemia in
remote settings raises opportunities and new strategic questions
for malaria management and elimination. In many regions of
endemicity, including southern Africa and Southeast Asia,
malaria is now a relatively uncommon disease, and asymptom-
atic low-density infections pose a signiﬁcant public health chal-
lenge. In these areas, hotspots of higher transmission can form
foci for wider reintroduction [40]. Strategies of focal screening
and treatment to identify and eliminate such parasite reservoirs
have been hampered by a lack of a highly sensitive diagnostic
test close to the site of sample collection [16]. This study dem-
onstrates that LAMP detects parasites with an accuracy similar
to that of PCR in a remote setting, removing the main logistical
barrier to implementation of focal screening and treatment
strategies. It will be important to assess the LAMP assay’s per-
formance in a variety of malaria-endemic settings to determine
the robustness of the platform.
The relative simplicity of the LAMP procedure and the low
infrastructure costs open a range of other research and moni-
toring opportunities by bringing molecular-level parasite detec-
tion within reach of national malaria control programs.
Although highly sensitive parasite detection may have limited
usefulness for routine fever case management in malaria-
endemic areas and the per-sample cost of LAMP remains well
above that of microscopy or RDT, LAMP may have speciﬁc ap-
plications in antenatal screening, screening in antimalarial drug
efﬁcacy trials, and resistance monitoring programs, vaccine
trials, and evaluations of other diagnostic tools [18–20]. Costs
may be further reduced by pooled screening [41, 42]. In higher-
resource countries, use of this LAMP assay in the diagnosis of
malaria in febrile returned travelers offers advantages of speed
and/or accuracy over current methods [23].
In conclusion, this malaria LAMP assay dramatically lowers
the detection threshold that can be achieved in routine malaria-
endemic settings. Future product improvements should include
scaling up throughput and lowering costs to address screening
requirements in malaria-endemic settings. As seen with the
recent introduction of malaria RDTs, introduction of novel di-
agnostic methods can open new avenues for malaria control
and elimination, as well as new challenges in identifying where
such capacity is best used.
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